CG Oncology, Inc. (CGON) vs Rhythm Pharmaceuticals, Inc. (RYTM)

CG Oncology, Inc. and Rhythm Pharmaceuticals, Inc. are both Biotechnology companies. Rhythm Pharmaceuticals, Inc. is the larger, with a market value of $6.8B against $6.1B — 1.1× the size. CG Oncology, Inc. grew revenue faster over the last twelve months: 840.8% against 53.5%. Rhythm Pharmaceuticals, Inc. has the higher net margin (−87.6% vs −3,602.7%) and the higher return on invested capital (0.00% vs −4,111.6%). Across the 17 metrics below, Rhythm Pharmaceuticals, Inc. leads on 12 and CG Oncology, Inc. on 5.

Valuation

Metric CGON RYTM Biotechnology median
P/E n/m n/m 7.88
P/S 956.63 28.21 11.47
P/B 5.79 65.71 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 793.45 26.83 10.73
Earnings yield (3.98%) (3.15%) (28.84%)
Free cash flow yield (3.01%) (2.23%) (23.03%)

Profitability

Metric CGON RYTM Biotechnology median
Gross margin (85.20%) 89.00% 65.16%
Operating margin (4,056.18%) (83.62%) 0.00%
Net margin (3,602.68%) (87.62%) 0.00%
Free cash flow margin (2,879.62%) (43.91%) 0.00%
Return on equity (26.41%) (461.65%) (57.72%)
Return on assets (25.11%) (51.91%) (49.22%)
Return on invested capital (4,111.64%) 0.00% 0.00%

Growth

Metric CGON RYTM Biotechnology median
Revenue growth (TTM) 840.79% 53.51% 5.64%
EPS growth (last fiscal year) (47.52%) 28.34% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric CGON RYTM Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 22.22 3.45 4.73
Net debt to EBITDA 3.88 2.04 0.96

Dividend

Metric CGON RYTM Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric CGON RYTM Biotechnology median
Market cap 6.09b 6.77b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack